Home » Woodcock Defends FDA as Experts Question Agency Regarding Antibiotics
Woodcock Defends FDA as Experts Question Agency Regarding Antibiotics
CHICAGO (Reuters) -- U.S. regulators need to provide a clear path for drug companies to develop new antibiotics and should consider offering financial incentives, experts told a Congressional panel on Wednesday.
They said doctors are running out of effective antibiotics, yet inconsistent regulatory guidelines at the U.S. Food and Drug Administration and the need to reduce the use of antibiotics has given companies little incentive to develop new drugs, experts told the House of Representatives Committee on Energy and Commerce's Subcommittee on Health.
Several experts acknowledged the need for more judicious use of existing antibiotics to slow the rise of antibiotic resistant strains of bacteria, but virtually all agreed that several routes are needed to solve the problem.
Robin Robinson, director of the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services, called antibiotic resistance a biodefense threat and said the federal government should provide financial incentives to encourage companies to develop new antibiotics.
He said his agency is supporting the development of new dual-purpose antibiotics that could be used to improve both public health and national security.
"The lengthy drug development process means that new classes of drugs to supplement or replace current ones are still years away at best," Robinson told the panel.
He noted that newer drugs are typically saved for the sickest patients, reducing their sales potential.
Dr. Barry Eisenstein, a senior vice president at Cubist Pharmaceuticals, has one answer for this -- extending the time patent protections are in place.
"We are approaching a "crisis point" with antimicrobial resistance," Eisenstein told the panel.
He complained that the FDA has been inconsistent in what it requires drug companies to prove to win marketing approval.
"Over the last decade, regulatory uncertainty, including ever-shifting FDA guidelines, have had a significant negative impact on approval of antibiotics," he added.
Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research at the FDA, agreed that more needs to be done to encourage drug companies to develop new antibiotics.
"The pipeline is diminished at a time when the need could not be greater," she said.
But she said scientists have disagreed over what the bar should be for proving an antibiotic works as well or better than existing drugs, especially for the treatment of common conditions like sinus infections or ear infections.
Approving an inferior drug that would be so widely used would only contribute to the problem of antibiotic resistance, she said.
"FDA plans to publish additional guidance on these methods within the next six months to establish new standards for antimicrobial drugs," Woodcock said.
Almost as soon as penicillin was introduced in the 1940s, bacteria began to develop resistance to its effects, prompting researchers to develop many new generations of antibiotics.
But their overuse and misuse have helped fuel the rise of drug-resistant "superbugs." The U.S. Centers for Disease Control and Prevention says most infections that people get while in the hospital are resistant to at least one antibiotic.
For example, half of all S. aureus infections in the United States are resistant to penicillin, methicillin, tetracycline and erythromycin.
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
Amgen, Zhejiang Beta Pharma Form Joint VentureFrom FOX Business
Amgen will form a joint venture with Chinese pharma firm to bring its colon cancer drug Vectibix to the Chinese market
Academic Tech Transfer Collaboration Required for Pharma R&D ModelFrom IT News Online
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
- All news »